FDA Approves KEYTRUDA® and KEYTRUDA QLEX , Each With WELIREG® , for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma
Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
FDA Grants Breakthrough Therapy Designation for Calderasib , an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® Plus Padcev® as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Met Primary Endpoints of Overall Survival and Progression-Free Survival in Certain Patients With Advanced or Recurrent Endometrial Cancer
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
Steadright Removes Titanbeach One Technical Report And Retains Qualified Geologist For New Technical Report
The Metal You've Never Heard Of Is Becoming a National-Security Priority -- and America Barely Mines It
